PALO ALTO, CA--(Marketwired - January 13, 2017) - Cooley advised Avidity Biosciences on its $16 million Series B financing. The round comprises $10 million in new capital and $6 million in convertible debt.
Takeda Pharmaceuticals, through its ventures group led the round, with new and existing investor participation from Alethea Capital, Alexandria Real Estate Equities, Brace Pharma, EcoR1 Capital, F-Prime Capital Partners, Moore Venture Partners and Tavistock Life Sciences.
Avidity is a privately held biotech company pioneering a new class of precision medicines -- Antibody-siRNA Conjugates (ASC) -- which combine the strengths of monoclonal antibodies and siRNA-based therapeutics. Avidity is working with partners to discover best-in-class drug candidates against important undrugged therapeutic targets.
The Cooley team advising Avidity included Josh Seidenfeld, Lesse Castleberry, Laura McDaniels and Kimberly Nguyen.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.
Contact Information:
Contact Information
Thomas Freeman